Accéder au contenu
Merck

Evaluation of LDH-A and glutaminase inhibition in vivo by hyperpolarized 13C-pyruvate magnetic resonance spectroscopy of tumors.

Cancer research (2013-06-01)
Prasanta Dutta, Anne Le, David L Vander Jagt, Takashi Tsukamoto, Gary V Martinez, Chi V Dang, Robert J Gillies
RÉSUMÉ

Hyperpolarized (13)C magnetic resonance spectroscopy provides a unique opportunity to detect real-time metabolic fluxes as a means to measure metabolic treatment responses in vivo. Here, we show that pharmacologic inhibition of lactate dehydrogenase-A suppressed the conversion of hyperpolarized (13)C-pyruvate to lactate in murine xenografts of P493 human lymphoma. In contrast, a glutaminase inhibitor reduced conversion of (13)C-pyruvate to alanine without affecting conversion of pyruvate to lactate. These results illustrate the ability to monitor biomarkers for responses to antimetabolic therapy in real-time, paving the way for clinical development of imaging biomarkers to monitor metabolic pharmacodynamics.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Pyruvic-1-13C acid (free acid), ≥99 atom % 13C, ≥99% (CP)
Sigma-Aldrich
Pyruvic-1-13C acid (free acid), API for Clinical Studies, ≥99 atom % 13C